EPRX
NASDAQ HealthcareEupraxia Pharmaceuticals Inc. - Common Stock
Biotechnology
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
�� 市场数据
| 价格 | $7.89 |
|---|---|
| 成交量 | 262,377 |
| 市值 | 485.26M |
| 贝塔系数 | 1.420 |
| RSI（14日） | 67.3 |
| 200日均线 | $6.66 |
| 50日均线 | $7.44 |
| 52周最高 | $9.32 |
| 52周最低 | $3.67 |
| Forward P/E | -11.86 |
| Price / Book | 7.84 |
🎯 投资策略评分
EPRX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (78/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 EPRX in your text
粘贴任何文章、记录或帖子 — 工具将提取 EPRX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-05-01.